GMP IPO Watch
Invesco India Pharma and Healthcare Fund
Regular Plan · Growth · Invesco Mutual Fund
Returns
Annualised (CAGR) returns for periods over a year.
Want to invest in this fund?
Open a free demat & trading account with Zerodha to invest in direct mutual funds with zero commission.
Rank in Category
| Period | This Fund | Category Avg. | Rank |
|---|---|---|---|
| 1W | +5.60% | +3.52% | 9 of 255 |
| 1M | +4.71% | +1.97% | 32 of 255 |
| YTD | -0.10% | +1.21% | 122 of 255 |
| INCEPTION | -0.66% | — | — |
Ranked among: Equity Scheme - Sectoral/ Thematic.
NAV History
Expense Ratio Trend
Portfolio · Sep 2026
Asset Allocation
- Equity87.01%
- Debt0.00%
- Cash12.99%
- Other0.00%
Market Cap Split
- Large Cap29.80%
- Mid Cap24.41%
- Small Cap32.80%
- Others12.99%
Fundamentals
| Fund | Category | |
|---|---|---|
| P/E | 54.00 | 41.94 |
| P/B | 9.80 | 6.29 |
| Price / Sales | 7.95 | 6.05 |
| Price / Cash Flow | 36.27 | 31.26 |
| Dividend Yield (%) | 0.28 | 0.60 |
Holdings · Sep 2026
| Holding | Sector | Weight | Change (1M) |
|---|---|---|---|
| Triparty Repo | Reverse Repo / TREPS | 20.56% | — |
| Max Healthcare Institute | Equity | 9.58% | — |
| Sun Pharmaceutical | Pharmaceuticals & Biotechnology | 8.99% | — |
| Sai Life Sciences | Pharmaceuticals & Biotechnology | 8.63% | — |
| Apollo Hospitals | Equity | 8.03% | — |
| Manipal Health Enterprises | Equity | 7.98% | — |
| Divis Laboratories | Pharmaceuticals & Biotechnology | 7.85% | — |
| Global Health | Equity | 7.00% | — |
| Dr. Agarwal's Health Care | Equity | 6.32% | — |
| Corona Remedies | Pharmaceuticals & Biotechnology | 6.13% | — |
| Torrent Pharmaceuticals | Pharmaceuticals & Biotechnology | 4.93% | — |
| Glenmark Pharmaceuticals | Pharmaceuticals & Biotechnology | 4.86% | — |
| Krishna Institute of Medical Sciences | Equity | 4.72% | — |
| Aster DM Quality Care | Equity | 1.99% | — |
| Net Receivables / (Payables) | Net Current Assets | -7.57% | — |
Sector Allocation · Sep 2026
Compare With Peers
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Nippon India Taiwan Equity Fund
Regular Plan · IDCW option
|
+59.64% | +47.37% | — | +23.17% |
|
HDFC Pharma and Healthcare Fund
Direct Plan · IDCW Option
|
+25.51% | +31.04% | — | +30.18% |
|
Kotak Healthcare Fund
Regular Plan · IDCW Option
|
+23.57% | — | — | +20.10% |
|
SBI Automotive Opportunities Fund
Direct Plan · IDCW
|
+22.37% | — | — | +11.34% |
|
Mirae Asset Healthcare Fund
Direct Plan · Growth
|
+21.28% | +24.36% | +16.89% | +22.00% |
|
ICICI Prudential US Bluechip Equity Fund
Regular Plan · IDCW
|
+20.32% | +18.33% | +12.09% | +15.77% |
|
PGIM India Healthcare Fund
Direct Plan · Direct IDCW
|
+20.03% | — | — | +11.89% |
|
Nippon India Japan Equity Fund
Regular Plan · Bonus Option
|
+18.89% | +19.86% | +8.28% | +8.45% |
|
HDFC Defence Fund
Regular Plan · IDCW Option
|
+18.80% | +34.56% | — | +36.67% |
|
HSBC India Export Opportunities Fund
Direct Plan · Growth
|
+18.74% | — | — | +9.24% |
More From Invesco Asset Management (India) Private Limited
| Scheme | 1Y | 3Y | 5Y | Since Inception |
|---|---|---|---|---|
|
Invesco India - Invesco Pan European Equity Fund of Fund
Direct Plan · IDCW
|
+29.22% | +21.43% | +14.27% | +8.53% |
|
Invesco India - Invesco Global Equity Income Fund of Fund
Direct Plan · IDCW
|
+24.72% | +24.82% | +16.84% | +12.29% |
|
Invesco India - Invesco EQQQ Nasdaq-100 ETF Fund of Fund
Direct Plan · Growth
|
+18.36% | +29.04% | — | +23.81% |
|
Invesco India Gold ETF Fund of Fund
Direct Plan · Growth
|
+17.69% | +31.00% | +23.21% | +10.42% |
|
Invesco India Gold Exchange Traded Fund
Regular Plan · Growth
|
+16.89% | +30.94% | +23.38% | +12.65% |
|
Invesco India Manufacturing Fund
Direct Plan · Growth
|
+15.40% | — | — | +8.26% |
|
Invesco India Business Cycle Fund
Direct Plan · IDCW
|
+13.01% | — | — | +28.23% |
|
Invesco India Consumption Fund
Direct Plan · IDCW
|
+12.61% | — | — | +11.29% |
|
Invesco India Small Cap Fund
Direct Plan · Growth
|
+11.56% | +20.66% | +18.82% | +23.11% |
|
Invesco India Focused Fund
Direct Plan · Growth
|
+8.90% | +22.24% | +14.53% | +21.58% |
About This Scheme
Investment Objective
To generate long term capital appreciation by investing predominantly in equity and equity related securities of the companies in Pharmaceuticals, Healthcare and allied sectors. There is no assurance that the investment objective of the Scheme will be achieved.
Stated Asset Allocation
Equity and Equity related instruments of companies in the Pharma, Healthcare and allied sectors : Min. 80% Max 100% ; Other equity and equity related instruments : Min. 0% Max 20% ; Money Market / Other Liquid Instruments : Min. 0% Max 20% ; Gold / Silver ETFs : Min. 0% Max. 20% ; Units issued by InvITs : Min. 0% Max 10%
Exit Load
Exit Load^: For each purchase of units through Lumpsum / switch-in / Systematic Investment Plan (SIP), Systematic Transfer Plan (STP) and IDCW Transfer Plan, exit load will be as follows: • if units are redeemed/switched out on or before 3 months from the date of allotment: 0.50% • if units are redeemed/switched-out after 3 months: Nil • Switch between the Plans under the Scheme: Nil ^Exit Load charged, if any, will be credited back to the scheme, net of Goods and Services Tax
Fund Managers
Mr. Aditya Khemani
Primary: Mr. Aditya Khemani
Mutual fund investments are subject to market risks. Read all scheme related documents carefully. Past performance is not indicative of future returns. Data is sourced from AMFI and fund houses via FinAPI and may lag official figures.